The problem becomes the pilot study and all the other stem cell trials which showed a really strong effect. It is hard to square the amazing result from the pilot with the results in the current trial.
One factor we haven’t really discussed which our CYP friends will love is the issue of manufacturing inconsistency. It is entirely possible that MSB’s cells work really well when good, but far too many batches are duds.
Novartis deal on the rocks, page-149
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |